Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on ACT-1004-1239 Pharmacokinetics
NCT05549531Phase 1Completed
- Sponsor
- Idorsia
- Start
- Oct 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACT-1004-1239 in multiple sclerosis (MS), sponsored by Idorsia. Primary endpoint: Maximum Plasma Concentration. Started Oct 2022; status: completed.
02
Drugs
ACT-1004-1239
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05549531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549531.